A Research Study to determine whether an investigational drug called vilazodone is safe and effective to treat symptoms of major depressive disorder in children and adolescents.

This is a research study that is being conducted by Dr. Robert Findling at Kennedy Krieger Institute to determine whether vilazodone, an SSRI antidepressant for the treatment of major depressive disorder (MDD), is safe and effective for children and adolescents (ages 7 to 17 years). Eligible children and adolescents, with symptoms of MDD, will visit the Kennedy Krieger Institute for nine outpatient visits over a 10-week period; each outpatient visit will last about 3 hours. Participants will receive psychological, behavioral, and medical testing, including behavioral assessments, physical examinations, blood draws, vital signs, ECGs, urine drug screen, and pregnancy testing for females. There will be a reimbursement of $50.00 for each outpatient visit to compensate individuals for time and travel during participation in the research study. For more information about this research study, please contact Rebekah Teetsel at (443) 923-2637 or by email at Teetsel@kennedykrieger.org

Research study Sponsor: Forest Research Institute, Inc.
PI: Robert Findling, M.D., M.B.A.
Johns Hopkins Medicine-IRB No. – IRB00054798